Investigational drug · Phase 2
Nab-placlitaxel
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Locally Advanced Breast Cancer, Triple Negative Breast Cancer, Metastatic Triple Negative Breast Cancers.
Phase 2Last checked: Nov 20, 2026Latest source record: Jun 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "Nab-placlitaxel"
First trial start
2024
Aug 26, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Nab-placlitaxel", any sponsor or status.
Conditions studied
As listed on its trial records.
- Locally Advanced Breast Cancer
- Triple Negative Breast Cancer
- Metastatic Triple Negative Breast Cancers
Approved drugs for the same conditions: Breast cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Nab-placlitaxel" as an intervention, largest first.
- Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With ChemotherapyActive, not recruiting
BioNTech SEIndustry
NCT06449222 · 83 participants · Start Aug 26, 2024 · Primary completion Aug 2028
Drug: BNT327 Dose Level 1 (DL1); BNT327 Dose Level 1 (DL2) and 7 more · For: Locally Advanced Breast Cancer; Triple Negative Breast Cancer; Metastatic Triple Negative Breast Cancers
Sites: Beverly Hills, California; Los Angeles, California; Palo Alto, California · 31 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Locally Advanced Breast Cancer
- DB-1303BNT323, trastuzumab pamirtecanPhase 35 trials
DualityBio Inc. · Metastatic Breast Cancer, HER2-positive Advanced Solid Tumor, Endometrial Cancer
- PalazestrantOP-1250Phase 32 trials
Olema Oncology, Inc. · Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
- Fixed of PertuzumabPhase 31 trial
Roche (Genentech) · Early Breast Cancer, Locally Advanced Breast Cancer, Inflammatory Breast Cancer
- RPH-051Phase 31 trial
R-Pharm · Locally Advanced Breast Cancer, Metastatic Breast Cancer
- SamuraciclibICEC0942, CT7001Phase 23 trials
Carrick Therapeutics Limited · Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer
- FWD1802Phase 22 trials
Forward Pharmaceuticals Co., Ltd. · Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer Stage IV
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.